Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 公共衛生學院
  3. 流行病學與預防醫學研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61026
標題: 促醒激素系統對睡眠品質與情緒障礙的影響
The effect of orexin system on sleep quality and mood disturbance
作者: Shih-Jie Lin
林詩婕
指導教授: 郭柏秀(Po-Hsiu Kuo)
關鍵字: 促醒激素,憂鬱症,睡眠品質,失眠,基因關聯性,酵素免疫分析法,
Orexin (hypocretin),Major depressive disorder,Sleep quality,Insomnia,Genetic association,Enzyme-linked immunosorbent assay (ELISA),
出版年 : 2013
學位: 碩士
摘要: 目的:近90%的重度憂鬱症(MDD)的患者都有睡眠障礙。此外,睡眠問題往往持續出現在緩解期。促醒激素(Orexin)是一種神經傳導分子又名食慾素(Hypocretin),會調節睡眠與清醒週期,並可能和MDD的神經病理學相關。目前的研究在探討促醒激素受體的基因變異、重鬱症和睡眠特徵的關聯。此外,一些過去針對檢測促醒激素濃度在異質性情緒相關疾病患者的腦脊液中表現的研究出現相互矛盾的結果。我們也另外評估了血漿中促醒激素濃度和睡眠品質及情緒狀態之間的關係。
方法:個案的收集是包含臨床診斷為重鬱症患者和健康對照組。匹茲堡睡眠質量指數(PSQI)用來衡量睡眠品質,切點大於5表示睡眠質量差。貝克憂鬱量表第二版(BDI-II)針對MDD患者症狀的嚴重程度來進行評估。我們在619名受試者針對兩個在促醒激素的兩個受體基因(HCRTR1, HCRTR2)上的單點核甘酸多型性(SNP; rs2271933、 rs2653349)進行基因分型中的檢測。在132位受試者的血漿測定促醒激素濃度採用ELISA kit。根據疾病狀態和睡眠品質,受試者被分成4個子群體。我們用Kruskal-Wallis檢定,來評估各子群體的促醒激素濃度。用回歸模型來檢定在同時調整性別和年齡後促醒激素受體的基因變異與促醒激素濃度,對於睡眠變量(如睡眠時間,睡眠效率,睡眠延遲,和失眠相關的變項)以及貝克憂鬱量表第二版分數的影響。
結果:促醒激素的單點核甘酸多型性在rs2271933(HCRTR1)顯示與PSQI總分(P = 0.006)有關連。個體帶有G等位基因會增加MDD的風險(OR= 1.48,P= 0.014)及日間功能較差(OR= 1.46,P =0.0124)。血漿促醒激素濃度在對照組且有良好的睡眠品質(中位數:0.67 ng/ml,P = 0.04)明顯高於其他子群(最低濃度是MDD且睡眠品質差:0.058 ng/ml)。促醒激素濃度較高對於發生睡眠潛伏期較長(OR= 0.39,P = 0.014)以及發生長的睡眠潛伏期頻率較高(OR= 0.36,P = 0.019)有保護作用。更高的睡眠效率是與較高的血漿促醒激素濃度(β= 2.48,P = 0.027)相關。同時,促醒激素濃度與BDI-II得分呈現負相關(β= -4.129,P = 0.016)。
結論:促醒激素受體上的基因變異與血漿促醒激素濃度對於睡眠相關的功能和情緒紊亂都有影響。越低的血漿促醒激素濃度與睡眠質量較差及更嚴重的憂鬱症狀有關係。
Objective: Nearly 90% of patients with Major depressive Disorder (MDD) report sleep disturbances. Additionally, sleep problems often persist in the remission period. Orexins are neuropeptides also named hypocretins that have known to regulate sleep-wakeful cycle and might be involved in the psychopathology of MDD. The current study aimed to examine associations of genetic variants in the orexin receptor genes with MDD and sleep features. Furthermore, few previous studies that examined orexin level in the cerebrospinal fluid of patients with heterogeneous mood related disorders exhibit conflicting results. We also evaluated the relationships between plasma orexin level and sleep quality and mood status.
Methods: We recruited clinical diagnosed MDD patients and healthy controls. Sleep quality was measured by Pittsburgh Sleep Quality Index (PSQI), with cut-off value 5 indicating poor sleep quality. Beck Depression Inventory II (BDI-II) was assessed for symptom severity in patients with MDD. We genotyped two markers in the orexin receptor genes (HCRTR1: rs2271933 and HCRTR2: rs2653349) in 619 subjects. Plasma orexin level was measured using an ELISA Kit in 132 individuals. They were divided into four subgroups according to disease status and sleep quality. We used Kruskal-Wallis test to evaluate orexin levels among subgroups. Regression models were used to test the effects of genetic variants and orexin level on sleep variables (e.g. sleep duration, efficiency, latency, and insomnia-related variables) and BDI-II while adjusted for sex and age.
Results: Marker rs2271933 (HCRTR1) showed association with PSQI scores (p=0.006). Individuals carry G allele had increased risk for MDD (OR=1.48, p=0.014), and exhibited poor daytime function (OR=1.46, p=0.0124). Plasma orexin level was significantly higher (p=0.04) in the control group with good sleep quality (median: 0.67) than other subgroups (the lowest level in MDD with poor sleep quality: 0.058). Higher orexin level had protective effects on quantity (OR=0.39, p=0.014) and frequency (OR=0.36, p=0.019) of sleep latency. Longer sleep efficiency is associated with higher plasma orexin level (β=2.48, p=0.027). Meanwhile, orexin level was negatively correlated with BDI-II score (β= -4.129, p=0.016).
Conclusion: Both genetic variants of orexin receptor genes and plasma orexin level show effects on sleep related features and mood disturbance. Lower plasma orexin level is associated with poor sleep quality and more severe depressive symptoms.
URI: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61026
全文授權: 有償授權
顯示於系所單位:流行病學與預防醫學研究所

文件中的檔案:
檔案 大小格式 
ntu-102-1.pdf
  目前未授權公開取用
485.62 kBAdobe PDF
顯示文件完整紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved